Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer
Nordling, Love; Backman, Max; Mezheyeuski, Artur; Lindblad, Joakim; et al.
Precision Spatial Biology
From tissue biology to novel diagnostic and therapeutic targets
Interactions between cancer cells and the surrounding stroma—immune cells, fibroblasts, and vascular cells—shape tumour initiation, progression, and responses to therapy.
Research
Our Research
Decoding the tumor landscape through tissue architecture, cell-to-cell interactions, and clinically anchored spatial biology.
Cancer is not just a collection of malignant cells, but a complex organ composed of various cell types interacting in a structured environment. Our lab aims to understand how this organization influences disease progression and response to therapy.
Lung Cancer
Mapping the lung cancer microenvironment to understand how immune context, stromal organization, and signaling states shape prognosis and treatment response.
Learn more arrow_forwardBreast Cancer
Studying early breast cancer lesions and localized tumor-stroma interactions to understand progression, recurrence risk, and response to radiotherapy.
Learn more arrow_forwardSelected work
Publications
In situ mapping of activated PDGFRβ defines a prognostic discrepancy between histological subtypes of NSCLC
Lindberg, Amanda; Hellberg, Louise; Grandon, Anaïs; Yu, Hui; et al.
Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity
He, Liqun; Testini, Chiara; Hekmati, Neda; Bonello, Altea; et al.
Updates
Group News
Funding, collaborations, and recent developments across the group’s spatial biology and cancer research programs.
New Funding
Lab receives new support for spatial cancer studies.
Continued investment strengthens our work on mapping tumor tissue architecture and clinically relevant biomarker discovery.
Conference
Group work highlights spatial interactions shaping tumor behavior.
Ongoing presentations and collaborations continue to connect tissue biology with translational oncology questions.
Recognition
Tissue-scale data integration continues to expand the lab’s clinical impact.
Combined pathology, imaging, and sequencing approaches remain central to the group’s strategy for biomarker and target discovery.